Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Abou-Alfa, D. Amadori, A. Santoro, A. Figer, J. Grève, C. Lathia, D. Voliotis, S. Anderson, M. Moscovici, S. Ricci (2011)
Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.Gastrointestinal cancer research : GCR, 4 2
S-W Park, J. Ludes-Meyers, D. Zimonjic, M. Durkin, N. Popescu, Claudio Aldaz (2004)
Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinomaBritish Journal of Cancer, 91
J. Llovet, C. Brú, J. Bruix (1999)
Prognosis of Hepatocellular Carcinoma: The BCLC Staging ClassificationSeminars in Liver Disease, 19
H. Qin, D. Iliopoulos, S. Semba, M. Fabbri, T. Druck, S. Volinia, C. Croce, C. Morrison, R. Klein, K. Huebner (2006)
A role for the WWOX gene in prostate cancer.Cancer research, 66 13
A. Bednarek, C. Keck-Waggoner, R. Daniel, K. Laflin, P. Bergsagel, K. Kiguchi, A. Brenner, Claudio Aldaz (2001)
WWOX, the FRA16D gene, behaves as a suppressor of tumor growth.Cancer research, 61 22
A. Paige, M. Zucknick, S. Janczar, J. Paul, C. Mein, K. Taylor, M. Stewart, C. Gourley, S. Richardson, T. Perren, T. Ganesan, J. Smyth, Robert Brown, H. Gabra (2010)
WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis.European journal of cancer, 46 4
M. Biselli, P. Andreone, A. Gramenzi, F. Trevisani, C. Cursaro, C. Rossi, S. Rosellini, C. Cammà, S. Lorenzini, G. Stefanini, G. Gasbarrini, M. Bernardi (2005)
Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 3 9
M. Nunez, D. Rosen, J. Ludes-Meyers, M. Abba, Hyunsuk Kil, R. Page, Andres Klein-Szanto, A. Godwin, Jinsong Liu, G. Mills, Claudio Aldaz (2005)
WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcomeBMC Cancer, 5
Llovet (2008)
Sorafenib in advanced hepatocellular carcinomaN Engl J Med., 359
L. Cancemi, C. Romei, Sara Bertocchi, G. Tarrini, I. Spitaleri, M. Cipollini, Debora Landi, S. Garritano, G. Pellegrini, A. Cristaudo, A. Pinchera, R. Barale, R. Elisei, S. Landi, F. Gemignani (2011)
Evidences that the polymorphism Pro‐282‐Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinomaInternational Journal of Cancer, 129
W. Guo, Z. Dong, Yuran Dong, Yan-li Guo, G. Kuang, Zhibin Yang (2013)
Genetic and epigenetic alterations of WWOX in the development of gastric cardia adenocarcinomaEnvironmental and Molecular Mutagenesis, 54
E. Płuciennik, R. Kusińska, Piotr Potemski, R. Kubiak, R. Kordek, A. Bednarek (2006)
WWOX--the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 32 2
J. Chiu, Y. Tang, T. Yao, A. Wong, H. Wong, R. Leung, P. Chan, T. Cheung, A. Chan, R. Pang, S. Fan, R. Poon, T. Yau (2012)
The use of single‐agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child‐Pugh B liver cirrhosisCancer, 118
C. Yeh, Kung-Hao Liang, Chen-Chun Lin, Ming-Ling Chang, Cheng‐Lung Hsu, C. Hung (2014)
A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinomaInternational Journal of Cancer, 134
T. Pressiani, C. Boni, L. Rimassa, R. Labianca, S. Fagiuoli, S. Salvagni, D. Ferrari, Enrico Cortesi, Camillo Porta, C. Mucciarini, L. Latini, C. Carnaghi, M. Banzi, S. Fanello, M. Giorgio, F. Lutman, Guido Torzilli, M. Tommasini, Roberto Ceriani, G. Covini, M. Tronconi, L. Giordano, N. Locopo, S. Naimo, Armando Santoro (2013)
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.Annals of oncology : official journal of the European Society for Medical Oncology, 24 2
R. Poon, S. Fan, C. Lo, Chi-leung Liu, J. Wong (2002)
Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver Function: Implications for a Strategy of Salvage TransplantationAnnals of Surgery, 235
G. Spinzi, S. Paggi (2008)
Sorafenib in advanced hepatocellular carcinoma.The New England journal of medicine, 359 23
Dongsheng Huang, Fuman Qiu, Lei Yang, Yinyan Li, Mei Cheng, Hui Wang, Guanpei Ma, Yunnan Wang, Min Hu, W. Ji, Yifeng Zhou, Jiachun Lu (2013)
The polymorphisms and haplotypes of WWOX gene are associated with the risk of lung cancer in southern and eastern chinese populationsMolecular Carcinogenesis, 52
Ileana Aderca, C. Moser, Manivannan Veerasamy, A. Bani-Hani, Ruben Bonilla-Guerrero, Kadra Ahmed, A. Shire, S. Cazanave, D. Montoya, Teresa Mettler, L. Burgart, D. Nagorney, S. Thibodeau, J. Cunningham, Jinping Lai, L. Roberts (2008)
The JNK inhibitor SP600129 enhances apoptosis of HCC cells induced by the tumor suppressor WWOX.Journal of hepatology, 49 3
V. Donati, G. Fontanini, M. Dell'omodarme, M. Prati, S. Nuti, M. Lucchi, A. Mussi, M. Fabbri, F. Basolo, C. Croce, R. Aqeilan (2007)
WWOX Expression in Different Histologic Types and Subtypes of Non–Small Cell Lung CancerClinical Cancer Research, 13
Yun Cho, H. Rhim, S. Noh (2011)
Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: A systematic reviewJournal of Gastroenterology and Hepatology, 26
J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. Parkin, D. Forman, F. Bray (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 136
Jilong Yang, Wei Zhang (2008)
WWOX tumor suppressor gene.Histology and histopathology, 23 7
F. Pimenta, D. Gomes, P. Perdigão, A. Barbosa, M. Romano‐Silva, M. Gomez, Claudio Aldaz, L. Marco, R. Gomez (2006)
Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomasInternational Journal of Cancer, 118
Kung-Hao Liang, Chen-Chun Lin, C. Yeh (2011)
GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.Pharmacogenomics, 12 7
J. Casey (2006)
Guidelines for the management of hepatocellular carcinomaNature Clinical Practice Gastroenterology &Hepatology, 3
Liver E.A.f.t.S.o.t. & Cancer E.O.f.R.a.T.o. EASL-EORTC Clinical Practice. (2012)
Guidelines: Management of hepatocellular carcinomaJ Hepatology, 56
J. Bruix, M. Sherman (2011)
Management of hepatocellular carcinoma: An updateHepatology (Baltimore, Md.), 53
A. Zhu (2006)
Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?The oncologist, 11 7
C. Gourley, A. Paige, K. Taylor, D. Scott, Nicola-Jane Francis, R. Rush, Claudio Aldaz, J. Smyth, H. Gabra (2005)
WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear.International journal of oncology, 26 6
M. Oken, R. Creech, D. Tormey, J. Horton, T. Davis, E. McFadden, P. Carbone (1982)
Toxicity and response criteria of the Eastern Cooperative Oncology GroupAMERICAN JOURNAL OF CLINICAL ONCOLOGY, 5
(2011)
GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treatedwith transcatheter arterial chemoembolization.Pharmacogenomics
S. Yendamuri, T. Kuroki, F. Trapasso, Adam Henry, K. Dumon, K. Huebner, N. Williams, L. Kaiser, C. Croce (2003)
WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer.Cancer research, 63 4
V. Mazzaferro, E. Regalia, R. Doci, S. Andreola, A. Pulvirenti, F. Bozzetti, F. Montalto, M. Ammatuna, A. Morabito, L. Gennari (1996)
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.The New England journal of medicine, 334 11
T.S. Yang, Hs Chang, Jen‐Shi Chen, Yung-Chang Lin, C. Liau, Wen‐Cheng Chang (2004)
Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 casesJournal of Gastroenterology, 39
Seda Ekizoğlu, M. Muslumanoglu, N. Dalay, N. Buyru (2012)
Genetic alterations of the WWOX gene in breast cancerMedical Oncology, 29
C. Yeh, Hui-Chin Chen, C. Sung, Cheng‐Lung Hsu, Chen-Chun Lin, K. Pan, J. Tseng, C. Hung (2011)
Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinomaBMC Cancer, 11
A. Cheng, Yoon-Koo Kang, Zhendong Chen, C. Tsao, S. Qin, Jun Kim, R. Luo, Jifeng Feng, S. Ye, Tsai‐Sheng Yang, Jianming Xu, Yan Sun, Houjie Liang, Jiwei Liu, Jie-jun Wang, W. Tak, H. Pan, K. Burock, J. Zou, D. Voliotis, Z. Guan (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.The Lancet. Oncology, 10 1
R. Aqeilan, C. Croce (2007)
WWOX in biological control and tumorigenesisJournal of Cellular Physiology, 212
A. Villanueva, V. Hernández-Gea, J. Llovet (2013)
Medical therapies for hepatocellular carcinoma: a critical view of the evidenceNature Reviews Gastroenterology &Hepatology, 10
Hwi-Young Kim, Joong-Won Park, J. Joo, Hyo-Hoon Kim, S. Woo, Woojin Lee, Chang‐Min Kim (2013)
Worse outcome of sorafenib therapy associated with ascites and Child‐Pugh score in advanced hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 28
1INTRODUCTIONWorldwide, hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed solid cancer and the third leading cause of cancer‐related mortality. If HCC cannot be completely removed, it usually grows very rapidly, resulting in a short overall survival (OS), ranging from 4 to 7 months. In recent years, owing to the advance of clinical staging systems, the therapeutic strategy of HCC has improved drastically, with many novel therapeutic modalities under clinical investigation. At this time, complete remission can be achieved for HCC patients by either surgical removal or nonsurgical ablation if diagnosed in the early stage, albeit a high recurrent rate of approximately 70% remains. Liver transplantation is considered to be the best treatment in some selected patients who fulfilled designated criteria, because the tumor and adjacent microinvasion were completely removed and most importantly, the cirrhotic liver was replaced. On the other hand, for patients with unresectable HCC, it is still debatable as to which treatment should be considered the “standard therapy.” In HCC patients without main portal vein thrombosis (PVT) or extrahepatic metastasis, namely Barcelona Clinical Liver Cancer (BCLC) stage B, transcatheter arterial chemoembolization (TACE) is believed to be an effective palliative treatment. For patients with BCLC stage C,
Asia-Pacific Journal of Clinical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.